Dedifferentiation into blastomere-like cancer stem cells via formation of polyploid giant cancer cells

N Niu, I Mercado-Uribe and J Liu

Our recent perplexing findings that polyploid giant cancer cells (PGCCs) acquired embryonic-like stemness and were capable of tumor initiation raised two important unanswered questions: how do PGCCs acquire such stemness, and to which stage of normal development do PGCCs correspond. Intriguingly, formation of giant cells due to failed mitosis/cytokinesis is common in the blastomere stage of the preimplantation embryo. However, the relationship between PGCCs and giant blastomeres has never been studied. Here, we tracked the fate of single PGCCs following paclitaxel-induced mitotic failure. Morphologically, early spheroids derived from PGCCs were indistinguishable from human embryos at the blastomere, polyploid blastomere, compaction, morula and blastocyst-like stages by light, scanning electron or three-dimensional confocal scanning microscopy. Formation of PGCCs was associated with activation of senescence, while budding of daughter cells was associated with senescence escape. PGCCs showed time- and space-dependent activation of expression of the embryonic stem cell markers OCT4, NANOG, SOX2 and SSEA1 and lacked expression of Xist. PGCCs acquired mesenchymal phenotype and were capable of differentiation into all three germ layers in vitro. The embryonic-like stemness of PGCCs was associated with nuclear accumulation of YAP, a key mediator of the Hippo pathway. Spheroids derived from single PGCCs grew into a wide spectrum of human neoplasms, including germ cell tumors, high-grade and low-grade carcinomas and benign tissues. Daughter cells derived from PGCCs showed attenuated capacity for invasion and increased resistance to paclitaxel. We also observed formation of PGCCs and dedifferentiation in ovarian cancer specimens from patients treated with chemotherapy. Taken together, our findings demonstrate that PGCCs represent somatic equivalents of blastomeres, the most primitive cancer stem cells reported to date. Thus, our studies reveal an evolutionarily conserved archaic embryonic program in somatic cells that can be de-repressed for oncogenesis. Our work offers a new paradigm for cancer origin and disease relapse.

Oncogene (2017) 36, 4887–4900; doi:10.1038/onc.2017.72; published online 24 April 2017

INTRODUCTION

A hallmark of many malignant tumors is dedifferentiated (immature) cells bearing little or no resemblance to the normal cells from which the cancer originated.1 A salient feature of dedifferentiation is the presence of giant cells with multiple copies of genomic DNA, referred to as polyploid giant cancer cells (PGCCs).2 A polyploid genome has been found in 37% of solid tumors.3

Polyploid cells were traditionally considered senescent and induction of polyploidy was traditionally considered a tumor suppressor mechanism as polyploid cells are believed to be unable to execute mitosis.4–7 However, PGCCs have been shown to generate daughter cells via budding8–12 and to contribute to immortalization, transformation and RAS-mediated tumor initiation and metastasis.13–15 Furthermore, tetraploid cells, not diploid cells, have been shown to be the main drivers of tumorigenesis.16,17 In addition, development of polyploidy has been shown to favor escape from senescence in chemotherapy-treated cancer cells.18–20 However, the mechanisms by which polyploidy gives rise to malignancy remain poorly defined.

We recently reported that PGCCs are cancer stem cells that can be induced from ovarian cancer cells by the hypoxia-mimetic agent CoCl2.21 We showed that PGCCs from ovarian cancer can grow into tumor spheroids, initiate tumor growth in nude mice and differentiate into other benign cell types in vitro and in vivo.21–24 These properties of PGCCs were also reported in colon cancer.23 A PGCC phenotype has recently been linked to CSL, a central node in Notch signaling.24 We also showed that growth and division of PGCCs involves a multistep programmed process, which we refer as to the giant cell cycle, with four distinct but overlapping phases, initiation, self-renewal, termination and stability, via which PGCCs give rise to new cancer-initiating cells.25 However, it is unclear how PGCCs acquire such stemness and which normal developmental stage PGCCs correspond to.

Polyploidy is common in plants and nonvertebrate animals but is generally incompatible with normal development of mammals except in a limited number of somatic cells or tissues.4,26,27 Intriguingly, blastomeres, which are produced by cleavage of the zygote in the human preimplantation embryo, frequently display mosaicism of diploidy and polyploidy. As embryogenesis progresses, mononucleated or multinucleated giant blastomeres are commonly seen due to frequent mitosis/cytokinesis failure and endoreplication.28–32 The proportion of embryos with more than five polyploid cells is 30.8% for morulae and 29.3% for blastocysts.33 A large proportion of polyploid blastomeres (50–80%) display high levels of genomic abnormalities.29–31,34–36 Therefore, formation of polyploid blastomeres appears to facilitate the development of compaction and subsequent blastocysts, and...
mitosis/cytokinesis failure may represent a normal mechanism regulating development of the preimplantation embryo.²⁸,²⁹,³⁷

The similarities between PGCCs and blastomeres raise the intriguing possibility that PGCCs are somatic equivalents of blastomeres. To investigate this possibility, we tracked the development of single PGCCs derived from ovarian cancer cells treated with paclitaxel.

RESULTS
PGCCs exhibited a developmental pattern similar to that of the blastomere-like embryo

The experimental design is shown in Figure 1A. Ovarian cancer cell lines Hey, SKOV3 and MDA-HGSC-1 were treated with paclitaxel overnight (16–18 h) to induce mitotic failure. The surviving cells entered an endoreplication cell cycle, grew as PGCCs and were allowed to recover for 7 days as previously described.²⁵ At day 7 (spheroid day 1 (sD1)), PGCCs were collected for three-dimensional (3D) culture or transferred to stem cell medium and allowed to grow as spheroids. From sD1 to sD21, spheroids were collected at different time points and fixed for immunofluorescence and immunohistochemical staining (IHC). At sD14, spheroids were reattached on cover slides and cultured with differentiation medium for an additional 14 days. At sD28, cell differentiation was evaluated via immunofluorescence and IHC.

At sD1, light microscopy showed that paclitaxel-treated Hey and SKOV3 cells grew as homogeneous PGCCs, and paclitaxel-treated MDA-HGSC-1 cells grew as spheroids with enlarged cells (Supplementary Figure 1A). The percentage of polyploid lines Hey, SKOV3 and MDA-HGSC-1 were treated with paclitaxel and allowed to recover for 7 days as previously described.²⁵ At day 7 (spheroid day 1 (sD1)), PGCCs were collected for three-dimensional (3D) culture or transferred to stem cell medium and allowed to grow as spheroids. From sD1 to sD21, spheroids were collected at different time points and fixed for immunofluorescence and immunohistochemical staining (IHC). At sD14, spheroids were reattached on cover slides and cultured with differentiation medium for an additional 14 days. At sD28, cell differentiation was evaluated via immunofluorescence and IHC. PGCCs showed greater spheroid-forming capacity (Figure 1B) than control cells (Figure 1C). Representative photos of spheroids are shown in Figure 1D.

To study the development of PGCCs, growth of single control PGCCs was monitored by light microscopy. Control Hey cells formed coral-like structures within 7–14 days (Figure 1E). Scanning electron microscopy showed long microvilli, ruffles and filopodia on the surface of Hey cells and Hey-derived spheroids (Figure 1F).

In contrast, Hey-derived PGCCs showed vacuolation of the cytoplasm (Figure 1G, white arrow). At sD3 and sD5, Hey cells budded from PGCCs asymmetrically, and at sD7 and sD14, spheroids were observed with mixed giant and small cells (Figure 1G). Nuclei of different sizes were found inside and on the surface of PGCCs (Figure 1H). Similar growth and morphology were seen in MDA-HGSC-derived PGCCs (Supplementary Figure 1E).

To visualize ultrastructural morphology during PGCC growth, we reattached individual Hey-derived PGCCs to ultra-low-attachment plates and tracked PGCC division by scanning electron microscopy. Unexpectedly, when PGCCs started to divide, they were covered by numerous uniform microvilli and were morphologically indistinguishable from blastomeres (Figure 1I).³⁸,³⁹ The cleavage dividing PGCCs resembled one-cell, two-cell, three-cell, four-cell, six-cell, compaction-like and 10- to 12-cell blastomeres and morulas (Figure 1I), similar to what is observed in the embryo body.⁴⁰ On 3D confocal scanning microscopy, single PGCCs formed blastocyst-like structures (Figure 1J, Supplementary Movies 1 and 2). 3D confocal scanning images of daughter cells from PGCCs are shown in Supplementary Figure 1F and Supplementary Movie 3. We concluded that PGCCs may undergo dedifferentiation toward embryo-like structures.

PGCCs can differentiate into three germ layers in vitro

To further determine the nature of PGCC-mediated stemness, we examined the phenotype of PGCCs following paclitaxel treatment. The cultures displayed mixtures of PGCCs and budded daughter cells of various morphologies (Figure 3A), including epithelium-like (Figure 3A(b)), fibroblast-like (Figure 3A(c)), mixed epithelial and mesenchymal (Figure 3A(d)), neuron-like (Figure 3A(e)) and very small spore-like (yeast-like) cells (Figure 3A(f)), suggesting that PGCCs are capable of differentiation into multiple lineages of daughter cells.
PGCCs exhibited a developmental pattern similar to that of blastomeres. (A) Experimental design. D, day; SEM, scanning electron microscopy; WB, western blotting; IF, immunofluorescence; IHC, immunohistochemistry; sD, scanning day. (B) Number (mean ± s.d.) of regular cancer-cell-derived spheroids and PGCC-derived spheroids per 5000 cells at sD7. Regular cancer-cell-derived spheroids: Hey, 7 ± 1.7; SKOV3, 2.3 ± 1.2; MDA-HGSC-1, 50.3 ± 5.9. PGCC-derived spheroids: Hey, 46.7 ± 7.8; SKOV3, 11 ± 2; MDA-HGSC-1, 174.0 ± 8.8. (C) Diameter (mean ± s.d.) of regular cancer-cell-derived spheroids (Hey, 363.0 ± 94.5; SKOV3, 182.5 ± 32.9; MDA-HGSC-1, 482.5 ± 91.5) and PGCC-derived spheroids (Hey, 104.2 ± 62.0; SKOV3, 84.0 ± 37.0; MDA-HGSC-1, 92.5 ± 22.5) at sD7. (D) Light microscopic images of control regular Hey cells, Hey-derived PGCCs and resulting spheroids at sD7. Scale bars, 50 μm. (E) Light microscopic images of ‘spheroid’ formed from a single regular Hey cell (20 μm in diameter) in serum-free stem cell medium. Scale bars, 50 μm. (F) Scanning electron microscopy images of regular Hey cell under mitosis (a) and spheroid derived from regular Hey cell (b). FL, filopodium; RF, ruffle. Scale bars, 10 μm. (G) Light microscopic images of spheroid formation from a single Hey-derived PGCC. Vacuole in the cytoplasm of PGCC is indicated with white arrowhead in panel sD2. The vacuolation is probably due to accumulation of autophagosomes. Scale bars, 50 μm. (H) Light microscopic nuclear morphology and size of PGCC and PGCC-derived spheroid with budding. Hoechst 33342 stain. Scale bars, 50 μm. (I) Scanning electron microscopy images of Hey-derived PGCCs. (a and b) PGCC mimicking single polyploid blastomere. (c–j) PGCC cleavage division mimicking blastomere division, including two-cell (c), three-cell (d), four-cell (e), compaction-like (g), PGCCs with multiple small cleaved daughter cells resembling a morula (h–j). Scale bars, 10 μm. (J) 3D confocal scanning images of Hey-derived PGCC (a and b) and spheroid derived from Hey-derived PGCC (c and d). (a and b) Blastocyst-like PGCC with budding (a) and cross-sectional view of panel a showing multiple nuclei in a single PGCC (b). Scale bars, 100 μm. (c and d) front (c) and back (d) views of PGCC-derived spheroid. Scale bars, 10 μm.
Next, we investigated the kinetics of activation of expression of alpha fetal protein (AFP), smooth muscle actin (SMA) and β3-tubulin (also known as PAX6), markers for endoderm, mesoderm and ectoderm, respectively, in Hey and SKOV3 cells. In Hey cells, mRNA levels of AFP and SMA were increased starting on day 1 of paclitaxel treatment, peaked at day 21 and decreased at day 28, by which time PGCC-derived daughter cells had formed (Figure 3B). In contrast, the mRNA levels of PAX6 remained relatively unchanged over this period. The protein levels of these three markers were much higher in Hey-derived PGCCs than in regular Hey cells and higher in daughter cells than in regular Hey cells (Figure 3C). SMA and β3-tubulin protein levels were higher in SKOV3-derived PGCCs than in regular SKOV3 cells and daughter cells (Figure 3C). However, there was no change in AFP expression at the mRNA or protein level in SKOV3 cells, suggesting that AFP expression may be cell line specific.

We then examined the ability of Hey-derived PGCCs to differentiate. In PGCC-derived spheroids but not in regular Hey cells, oil red staining, a marker of adipose differentiation, was observed when spheroids were cultured in adipogenesis medium (Figure 3D); blue drops indicating sulfate chondroitin, a marker of chondrogenesis, were observed when spheroids were cultured in chondrogenesis medium (Figure 3E); and scale-like osteogenin-positive signals were observed when spheroids were cultured in osteogenesis medium (Figure 3F). Expression of AFP, SMA and β3-tubulin was detected when spheroids were cultured in stem cell medium (Figure 3G).

When Hey cells were cultured on a scaffold membrane, PGCCs grew mainly on the membrane surface as normal fallopian-tube-like epithelial cells, the known origin of high-grade serous carcinoma, whereas regular Hey cells invaded into the membrane (Figure 3H). These findings demonstrated that PGCCs were capable of growing back into the normal cell of origin of ovarian cancer.

Differentiation capability of PGCCs depends on nuclear location of YAP

YAP, a critical Hippo pathway protein, is involved in the regulation of stem cells and cancer development and is responsible for cytokinesis-failure-induced activation of tumor suppressor pathway. We examined the role of YAP in the regulation of stemness and differentiation of PGCCs. YAP was located mainly in the cytoplasm of regular Hey cells and daughter cells but predominantly in the nuclei of PGCCs (Figures 4a and b). Treatment of PGCCs with dobutamine, which inhibits YAP nuclear translocation, abolished nuclear localization of YAP (Figure 4a). Spheroids formed by Hey-derived PGCCs differentiated into endoderm as indicated by AFP, c-Kit and CXCR4 expression (Figure 4c, upper panels), but dobutamine inhibited this differentiation, as indicated by lack of daughter cells and lack of expression of markers (Figure 4c, lower panels). Spheroids formed by Hey-derived PGCCs also differentiated into astrocyte-like cells as indicated by GFAP expression (Figure 4d, upper panels), and again, dobutamine inhibited this differentiation (Figure 4d, lower panels). GATA6, a key regulator in generation of primitive endoderm, was also activated in PGCCs induced by paclitaxel or CoCl2 (Supplementary Figure 3A), suggesting that GATA6 may be a critical mediator for early embryonic-like development in somatic cells, similar to that in the embryo. We also observed endoderm differentiation of PGCCs induced by CoCl2 (Supplementary Figure 3B).

PGCC-derived spheroids transform into mixed germ cell tumors and carcinoma of different grades in vivo

To determine the nature of tumors that developed from PGCC-derived spheroids in vivo, we injected green fluorescence protein (GFP)-ubiquitin-labeled control Hey-cell-derived spheroids (10 000 cells) and PGCC-derived spheroids (1000 cells) collected at sD7 into the subcutis or testis of SCID (severe combined immunodeficiency) mice. All the tested spheroids formed subcutaneous or testis tumors, but PGCC-derived spheroids took significantly longer to form 1 cm tumors (60–120 days vs 30 days).

Control Hey-cell-derived spheroids formed high-grade carcinomas (Figure 5A(a)). In contrast, PGCC-derived spheroids formed a spectrum of tumors, including mixed germ cell tumor composed of dysgerminoma and embryonic carcinoma (Figures 5A(b) and A(c)), dysgerminoma with skeletal muscle differentiation (Figure 5A(d)), embryonic carcinoma (Figures 5A(e) and B(g)), embryonic carcinoma transitioning into mesenchymal morphology (Figure 5A(f)), high-grade carcinoma (Figure 5A(g)), mixed high-grade and low-grade carcinoma (Figure 5A(h)) and benign squamous cells (Figure 5A(i)). Mixed germ cell tumors were observed in (19%) mice with subcutaneous and intratesticular injections (20%) and no tumors in the control groups (P < 0.0001; Table 1).

To further determine the level of maturation of germ cells, we performed IHC on continuous sections. Carcinoma from control cells showed high-grade morphology, weak expression of keratin and no expression of germ cell markers SALL4 and OCT4 (Figure 5B). Dysgerminoma and embryonic carcinoma from PGCC-derived spheroids showed SALL4 staining but different levels of epithelial maturation as reflected in different intensities of cytokeratin and OCT4 staining (Figure 5B). Results of additional IHC to characterize the germ cell tumor are shown in Supplementary Figures 4A and B. We also demonstrated that germ cell tumors were derived from human, not mice, using GFP-ubiquitin-labeled cancer cells (Supplementary Figure 4C).

The above findings suggested that PGCCs were capable of differentiation into primordial germ cells and a wide spectrum of epithelial neoplasms from high-grade to benign tumors.

PGCC-derived daughter cells acquire drug resistance and mesenchymal features

To determine whether PGCC-derived daughter cells differ from parental regular cancer cells, we first analyzed the apoptotic response and sensitivity to paclitaxel. Untreated daughter cells had more polyploid cells than regular cells did (Figure 6a). Following paclitaxel treatment, the total apoptotic percentage (Q2 +Q4) was lower in daughter cells than regular cells (Figure 6b). The IC50 values for paclitaxel and vincristine were significantly higher for daughter cells than for regular cells, but the IC50 values for olaparib and topotecan did not differ between the two cell types (Figure 6c, Supplementary Table 2), demonstrating that paclitaxel-induced PGCCs can generate daughter cells chemoresistant not only to paclitaxel but also to other drugs.

The daughter cells were less invasive than the regular cancer cells (Figures 6d and e). Both PGCCs and daughter cells displayed increased expression of pan-cytokeratin, mesenchymal markers vimentin, fibronectin and N-cadherin, and epithelial–mesenchymal transition regulatory transcription factors Snail, Slug and Twist 2 and decreased expression of β-catenin (Figure 6f). Morphologic features of epithelial–mesenchymal transition were also observed in xenografts (Figure 6g). Tumors from regular cancer cells grew faster than tumors from PGCC-derived daughter cells (Figure 6g). The regular cancer-cell-derived tumors had predominantly epithelial cell morphology, whereas the daughter-cell-derived tumors had mesenchymal-shaped cells with increased heterogeneity (Figure 6g), suggesting that decreased proliferation together with acquired ability to differentiate via epithelial–mesenchymal transition confers acquired resistance to paclitaxel in daughter cells.
Formation of PGCCs and dedifferentiation of ovarian cancer after chemotherapy

We reasoned that we should be able to observe dedifferentiation following chemotherapy in ovarian cancers in patients. Toward this end, we examined paired specimens of human ovarian cancer obtained before and after chemotherapy. Although the pre-chemotherapy specimens had relatively homogeneous cells, the post-chemotherapy specimens had increased numbers of...
anaplastic PGCCs with marked variation in size and large bizarre nuclei (Figures 7A and B). Post-chemotherapy specimens had small daughter cells budded off from a single PGCC (Figures 7B and C, black arrow) and erythrocyte-like cells within the cytoplasm of PGCCs (Figures 7Bd, blue arrow). The nuclear area of budded daughter cells was significantly smaller than that of pre-chemotherapy cancer cells (Figure 7D).

After chemotherapy, 3 of 38 samples were positive for OCT4 (in cytoplasm and nuclei), 12 of 38 were positive for NANOG (mainly in cytoplasm) and 17 of 38 were positive for SOX2 (mainly in cytoplasm).
nuclei); before chemotherapy, no cases were positive for OCT4 or NANO(G, and only 2 of 38 were positive for SOX2 (mainly in the cytoplasm; Figure 7E). Nuclear localization of YAP was observed in the three cases of post-chemotherapy not in pre-chemotherapy control (Figure 7E). These findings demonstrated that treated cancer cells showed increased expression of embryonic stem cell markers in a subset of post-chemotherapy treated ovarian cancers.

Xist expression is generally associated with differentiated state of somatic cells. We examined Xist expression in regular cancer cells and PGCCs. Xist was strongly expressed in nuclei of cancer and stromal cells before chemotherapy but was largely lost in nuclei of PGCCs after chemotherapy (Figure 7F), further supporting the concept that PGCCs acquired embryonic-like stemness.

DISCUSSION

In this work, we demonstrated that PGCCs are the somatic equivalent of blastomeres. This study validated our early reports that showed embryonic-like stemness of PGCCs. By using CoCl2 to induce hypoxia or paclitaxel to induce mitotic failure, we
Figure 5. Formation of germ cell tumors and carcinomas of different grades from PGCC-derived spheroids. (A) Hematoxylin–eosin (H&E)-stained images from xenografts formed by control Hey cells and PGCC-derived spheroids. (a) control Hey cells; (b) low-power view of multiple foci of dysgerminoma in a background of carcinoma; (c) high-power view of dysgerminoma showing vesicular nuclei and clear cytoplasm of tumor cells characteristic of primordial germ cells; (d) dysgerminoma with skeletal muscle differentiation; (e) mixed dysgerminoma and embryonic carcinoma; (f) dysgerminoma with mesenchymal morphology; (g) high-grade carcinoma; (h) mixed high- and low-grade tumor with high-power view; (i) benign squamous cells with immunohistochemical staining against cytokeratin. (B) H&E staining and IHC for SALL4, cytokeratin (CK) and OCT4 on continuous sections of xenografts formed by regular Hey cells (Control) and malignant germ cell tumors generated from spheroids derived from PGCCs. In control xenografts formed by regular Hey cells, cancer cells were positive for human-specific CK, but not for OCT4 and SALL4. In xenografts formed by PGCC-derived spheroids, all of the cancer cells were positive for human-specific CK, and there were clusters of cells positive for OCT4 and SALL4. Gray circles show the same subpopulations. Black cycle indicates cytokeratin positive cells. Scale bars, 50 μm.
showed that PGCCs acquired the properties of blastomeres, including differentiation into three germ layers and formation of germ cell tumors and carcinoma of different grades as well as benign tissue, similar to what has traditionally been referred to as teratocarcinomas except that the tumors described here were generated via reprogramming from epithelial carcinoma cells. Our method demonstrated that PGCCs may be a missing link that connects stem cells and induced pluripotent stem cells. More recently, the work of Nobel laureates Gurdon and Yamanaka has made clear that much development is due to maturation arrest of differentiation can lead to tumor initiation. The embryonic origin of cancer was proposed as early as the late nineteenth century by Cohnheim in 1867.49 However, direct experimental evidence for an embryonic origin of cancer was lacking until Stevens demonstrated in 1964 that the embryonic stem cells from murine blastocysts could develop into teratoma/teratocarcinoma;50,51 and Pierce demonstrated in the same year that single embryonic carcinoma cells could generate multiple lineages of benign cells.52 In 1971 that carcinoma can generate benign cells.53 This work led Pierce to propose that the hereditary potential for different grades as well as types of tumors. The level of dedifferentiation varies according to the type of stressors and duration of stress and the cell type: the longer the giant cell cycle, the closer the resulting cells to the primitive stage and the greater level of their development potential for different grades as well as types of tumors.

Our findings also provide new insights into chemotherapy resistance. Paclitaxel is a microtubule poison, its therapeutic effects are largely due to arrest of cells at mitosis, which leads to mitotic catastrophe and cancer cell death via apoptosis or necrosis or chromosomal missegmentation.64,65 However, resistance to paclitaxel is common in patients. Polyploidy has recently been proposed to be the main cause of docetaxel resistance.66 Our studies provide strong experimental evidence supporting a central role of polyploidy in drug resistance by providing most primitive cancer stem cells for drug resistance and disease relapse. In summary, our findings constitute strong experimental evidence that PGCCs function as blastomere-like stem cells to facilitate the neoplastic evolution in response to various genetic/epigenetic or environmental stressors. Blocking formation of polyploidy and redirecting differentiation of PGCCs toward benign lineages may be promising therapeutic approaches for cancer.

| Group | Diagnosis | Injection site | Testis (percentage) | P-value |
|-------|-----------|----------------|---------------------|---------|
| Control | Mixed germ cell tumor | 0 (0) | 0 (0) | |
| PGCCs | High-grade carcinoma | 8 (100) | 8 (100) | |
| PGCCs | Mixed germ cell tumor | 3 (19.0) | 2 (20.0) | <0.0001 |
| Carcinoma | High grade | 8 (50) | 5 (50.0) | |
| Low grade | 0 (0) | 0 (0) | |
| High grade/low grade | 5 (31.0) | 3 (30.0) | |
| Abbreviations: PGCC, polyploid giant cancer cell; SCID, severe combined immunodeficiency. |
confluence, the cells were treated with paclitaxel (500 nM, Sigma, St Louis, MO, USA) overnight (16–18 h); the cells were then allowed to recover for 7 days to form PGCCs. Thirty-eight paired samples of archived, paraffin-embedded high-grade ovarian serous carcinoma obtained before and after six cycles of paclitaxel- and carboplatin-based chemotherapy were subjected to histology analysis and IHC for different markers. Use of these samples was approved by MD Anderson’s Institutional Review Board.

**Spheroid formation**

At recovery day 7 after paclitaxel treatment, PGCCs were dissociated and cultured with FBS-free stem cell medium (Gibco, Grand island, NY, USA) in low-attachment plates (Corning, Corning, NY, USA). A total of 5000 test cells in 3 ml of stem cell medium were cultured in 60 mm low-attachment dishes. Spheroid formation was then observed for an additional 14 days. Spheroids more than 100 μm in diameter were counted. Spheroids were

**Figure 6. Acquisition of drug resistance and increased expression of epithelial and mesenchymal markers in PGCC-derived daughter cells.**

(a) Percentage of polyploid cells (blue dots in gate P2) among regular Hey and SKOV3 cells and PGCC-derived daughter cells. (b) Percentage of apoptotic cells (Q2+Q4) among regular Hey and SKOV3 cells and PGCC-derived daughter cells after exposure to 100 nM PTX and recovery for 48 h. (c) Sensitivity of PGCC-derived daughter cells compared with corresponding regular cancer cells to PTX, vincristine, carboplatin, olaparib and topotecan (24 h treatment). Results are presented as the ratio of the IC50 value for daughter cells to the IC50 value for regular cancer cells. The IC50 values are indicated in Supplementary Table 2. (d and e) Invasion ability of regular Hey and SKOV3 cells and PGCC-derived daughter cells. In matrigel-transwell invading experiments, the number of invaded regular Hey cells (72.6 ± 11.8/cm²) and SKOV3 cells (63.8 ± 8.7/cm²) was higher than the number of invaded daughter cells (Hey daughter, 32.7 ± 3.8/cm²; SKOV3 daughter, 28.6 ± 3.4/cm²). (f) Expression of epithelium-related and mesenchyme-related protein in tested cell lines, detected by western blotting. Reg, regular cancer cells; PG, PGCCs at day 7 after paclitaxel treatment; Dau, daughter cells. (g) Acquisition of mesenchymal phenotype in xenografts generated by PGCC-derived daughter cells. Left panel, tumor nodules of regular control and daughter cell groups are indicated with blue and black arrows, respectively. Right upper panel, nodule size of test groups. Right lower panels, H&E staining of xenografts. Similar-sized cancer cells in control are indicated with black arrows, and heterogeneous-size cancer cells in the daughter group are indicated with blue (epithelial-like) and green (mesenchymal-like) arrows.
also grown from PGCCs induced by CoCl2 as previously described; these spheroids were used to study endoderm differentiation.

Hematoxylin–eosin staining, immunohistochemistry and immunofluorescence
Hematoxylin–eosin staining, IHC and single and double immunofluorescence labeling were performed as described previously. Primary antibodies are listed in Supplementary Table 1.

β-Gal staining
β-Gal staining for senescence was performed as described previously.

Western blot analysis
Western blot analysis was performed as described previously.

Scanning electron microscopy
Attached PGCCs, spheroids and control regular cancer cells were examined with scanning electron microscopy as previously described.

Live 3D confocal scanning of early-stage PGCC-derived spheroids
GFP-ubiquitin-labeled Hey cells were treated with paclitaxel, allowed to recover in regular medium for 7 days, and then cultured with stem cell medium for 2 days. The cells and spheroids were stained with Hoechst 33342 and multiply scanned at XY axis along the Z direction; images were reconstructed with a Carl Zeiss 710 confocal microscope (Zeiss, Thornwood, NY, USA).

Xist RNA in situ hybridization
An RNAscope immunofluorescence kit (Advanced Cell Diagnostics, Hayward, CA, USA) was used on fixed cells on coverslips and an RNAscope
kit (Advanced Cell Diagnostics) on sections of human ovarian cancer according to the manufacturer’s protocol.

Analysis of stemness and differentiation capacity of PGCCs
PGCCs were cultured with stem cell medium for 7 days, reattached on coverslips and cultured on Matrigel (Corning)-coated coverslips with specific differentiation media (Gibco: adipogenesis, chondrogenesis and osteogenesis differentiation media; Stem Cell Technologies (Cambridge, MA, USA): endoderm differentiation, astrocyte-inducing, differentiation and mature media) according to the manufacturer’s protocols. Dobutamine (10 μM) was used to block the nuclear accumulation of YAP. The cells were then fixed with 10% paraformaldehyde/PBS for immunofluorescence staining.

Oil red staining for fat vacuoles was performed with a lipid staining kit (Zenbio, Research Triangle Park, NC, USA) and Alcian blue staining for chondroitin was performed with an Alcian blue pH 2.5 periodic acid-Schiff staining kit (Fisher Scientific, New Kensington, PA, USA) according to the manufacturer’s protocol. Immunofluorescence staining against osteogenin, AFP, CXCR4, c-Kit, YAP, GFAP, CD133, SMA and β3-tubulin was performed as described previously.70 Primary antibodies are listed in Supplementary Table 1.

Flow cytometry
ALDH1-FITC, CD133-PE and CD117-APC were incubated with Hey-derived PGCCs at recovery day 7 (dD1) and analyzed by a FACS Canto II flow cytometer (BD Biosciences, San Jose, CA, USA). The ovarian cancer cells stained with propidium iodide (Sigma) were also analyzed by a FACS Canto II flow cytometer.

Invasion analysis and 3D culture
Invasion assay was performed in a matrigel invasion chamber (BD Biosciences, Bedford, MA, USA) according to the manufacturer’s protocol. The 3D spatial structure of control and PGCC-derived spheroids was determined with an Alvetex scaffold system (AMS Biotechnology, Cambridge, MA, USA) according to the manufacturer’s protocol.

Reverse transcription and real-time quantitative PCR
Total RNA from PGCCs at different time points (days 1, 3, 7, 14, 21, 28) was extracted and purified using an RNeasy Kit (Qiagen, Dusseldorf, Germany); 1 μg of total RNA was used for reverse transcription with Iscript Reverse Transcription Supermix (Bio-Rad, Hercules, CA, USA), and qPCR reactions were performed in

Figure 8. Schematic of blastomere model for cancer origin and disease relapse. (A) Blastomere-mediated embryogenesis during differentiation (normal development) and subsequent tumor formation associated with maturation arrest of stem cells in different organs during adulthood. Following gamete fusion (sex), zygote will develop into blastomeres, compaction, morula and blastocyst/ICM. Inner cell mass will develop into primordial germ cells, which will proceed with spermatogenesis (male) or oogenesis (female); while three germ layers will develop into somatic tissues containing stem cells of primitive multipotency (a), intermediate potency (b) or mature stable cells (d). Maturation arrest at different developmental hierarchies leads to formation of germ cell tumors (GCTs) or germ-layer-specific tumor with different grades of malignancy: high-grade tumors (HG), low-grade tumors (LG), benign tumors (BN) or metaplasia (MP). BM, blastomere; Endo, endoderm; Ecto, ectoderm; Meso, mesoderm; GCs, germ cells; ICM, inner cell mass. M’ and M represent different genetic/epigenetic mutations acquired in germ cells and somatic cells respectively during embryonic or in adult development. a, b, c, and d represent different levels of hierarchy in normal development. (B) Induced blastomere-like-mediated oncogenesis via dedifferentiation (reprogramming) of somatic cells. Following mitotic failure induced by paclitaxel (PTX), somatic cells initiate endoreplication to generate PGCCs, which grow into blastomere-like (BM-like), compaction-like and morula-like cell masses (self-renewal) and then differentiate into structures morphologically similar to the blastocyst with inner cell mass and then into the three germ layers and germ cell lineage (termination). The entire process mimics development of preimplantation embryo via the giant cell cycle (preimplantation-like). The germ cells and primitive stem cells arrest at different developmental hierarchies to generate germ cell tumors (GCTs) and somatic tumors with different levels of malignancy. a’, b’, c’ and d’ correspond to levels of developmental hierarchy following stress-induced reprogramming.

Oncogene (2017) 4887–4900
triplicate as described previously.\textsuperscript{70} The primers for OCT4, NANOG, DAZL, AFP, SMA and PAX6 were designed as described previously.\textsuperscript{71,72} Changes in gene expression were calculated by using the $\Delta\Delta Ct$ method.

Tumorigenesis in mice from spheroids or daughter cells derived from single PGCCs
Spheroids derived from single PGCCs and control cells were cultured in stem cell medium for 7 days. For tests injection, single spheroids in 10 μl of PBS were injected one spheroid per mouse into the testis of male SCID mice 2 months of age (16 injections) and controls (eight mice). Daughter cells from single PGCC-derived colonies were isolated and passaged for more than 10 generations to obtain stable populations. Then $10^4$ daughter or control cancer cells in 50 μl of PBS and 50 μl of Matrigel (Corning) were injected subcutaneously into the SCID mice. When tumors reached 1 cm, the mice were killed, and the tumor nodules were harvested for histology and IHC. Tumor types were diagnosed by two pathologists (JL and NN). The primary antibodies are listed in Supplementary Table 1. The use and IHC. Tumor types were diagnosed by two pathologists (JL and NN). The primary antibodies are listed in Supplementary Table 1. The use and care of mice were approved by the MD Anderson’s Institutional Animal Care and Use Committee.

Statistics
The number and diameter of spheroids were assessed in randomly selected fields by light microscopy ($\times 4$) and analyzed with $\times$ test or one-way analysis of variance. Relative folds of IC50 of tested drugs, diagnosis and differentiation of xenografts were analyzed with $\chi^2$ test. Significance was defined as $P<0.05$, and all tests were two-sided. Statistical tests were performed with SPSS software (SPSS for Windows version 22.0, SPSS Inc, Chicago, IL, USA). All quantitative results were presented as mean ± s.d.

CONFLICT OF INTEREST
The authors declare no conflict of interest.

ACKNOWLEDGEMENTS
This work was supported in part by a multi-investigator grant from the Cancer Prevention and Research Institute of Texas (JL); a Sister Institution Grant from MD Anderson Cancer Center Global Academic Programs; and National Cancer Institute Cancer Center Support Grant CA016672, which supported the High Resolution Electron Microscopy Facility. We thank Kim Vu for image artwork and Stephanie Deming for editorial assistance. We thank many colleagues for helpful discussions. We apologize for many investigators who embraced embryonic origin of tumor or its variants over past two centuries whose work can not be cited and discussed due to space limitation.

REFERENCES
1 Kumar V, Abbas AK, Fausto N, Aster J. Neoplasia. Robbins and Cotran Pathologic Basis of Disease. Saunders Elsevier: Philadelphia, PA, USA, 2010; Chapter 7, pp 262–270.
2 Zhang S, Mercado-Uribe I, Xing Z, Sun B, Kuan J, Liu J. Generation of cancer stem-like cells through the formation of polyplody giant cancer cells. Oncogene 2014; 33: 116–128.
3 Zack T, Schumacher SE, Carter SL, Cherniack AD, Saksena G, Tabak B et al. Pan-cancer patterns of somatic copy number alteration. Nat Genet 2013; 45: 1134–1140.
4 Ganem NJ, Pellman D. Limiting the proliferation of polyplody cells. Cell 2007; 131: 437–440.
5 Munoz-Espin D, Serrano M. Cellular senescence: from physiology to pathology. Not Rev Mol Cell Biol 2014; 15: 482–496.
6 Ewald JA, Desotelle JA, Wilding G, Jarrard DF. Therapy-induced senescence in cancer. J Natl Cancer Inst 2010; 102: 1536–1546.
7 Campisi J. Aging, cellular senescence, and cancer. Annu Rev Physiol 2013; 75: 685–705.
8 Erenpreisa J, Kalejs M, Ianzini F, Kosmacek EA, Mackey Y, Spits C et al. Multinucleation in human morulae and blastocysts using co-culture and SEM. Cell Biol Int 2013; 37: 635–651.
9 Erenpreisa J, Kalejs M, Ianzini F, Kosmacek EA, Mackey Y, Spits C et al. Multinucleation in human morulae and blastocysts using co-culture and SEM. Cell Biol Int 2013; 37: 635–651.
10 Sundaram M, Guernsey DL, Rajaraman MM, Rajaraman R. Neosis: a novel type of cell division in cancer. Cancer Biol Ther 2004; 3: 207–218.
11 Walen KH. Budded karyoplasts from multinucleated fibroblast cells contain centrosomes and change their morphology to mitotic cells. Cell Biol Int 2005; 29: 1057–1065.
12 Puig PE, Guille MN, Bouchot A, Droin N, Cathelin D, Bouyer F et al. Tumor cells can escape DNA-damaging cisplatin through DNA endoreduplication and reversible polyplody. Cell Biol Int 2008; 32: 1031–1043.
13 Leikam C, Hufnagel AL, Otto C, Murphy DJ, Mulhing B, Kneitz S et al. In vitro evidence for senescent multinucleated melanocytes as a source for tumor-initiating cells. Cell Death Dis 2015; 6: e1711.
14 Zhang S, Mercado-Uribe I, Sood A, Bast RC, Liu J. Coevolution of neoplastic epithelial cells and multilineage stroma via polyplod giant cells during immortalization and transformation of muliferrum epithelial cells. Genes Cancer 2016; 7: 60–72.
15 Wehuta Z, Lin Q, Ramoth AJ, Fan D, Fidler I. Formation of solid tumors by a single multinucleated cancer cell. Cancer 2011; 117: 3442–3452.
16 Fujiwara T, Bandi M, Nitta M, Ivanova EV, Bronson RT, Pellman D. Cytokinesis failure generating tetraploids promotes tumorigenesis in p53-null cells. Nature 2005; 437: 1043–1047.
17 Davoli T, de Lange T. Telomere-driven tetraploidization occurs in human cells undergoing crisis and promotes transformation of mouse cancer. Cancer Cell 2012; 21: 765–776.
18 Wang Q, Wu PC, Dong DZ, Ivanova I, Chen H, Zeladiti S et al. Polyploidy road to therapy-induced cellular senescence and escape. Int J Cancer 2013; 132: 1505–1515.
19 Mosieniak G, Sliwinska MA, Alster O, Strzeszewska A, Sunderland P, Pitchot M et al. Polyploidy formation in doxorubicin-treated cancer cells can favor escape from senescence. Neoplasia 2015; 17: 882–893.
20 Chakrada S, Elmore LW, Gewirtz DA. Is senescence reversible? Curr Drug Targets 2015; 17: 460–466.
21 Zhang S, Mercado-Uribe I, Liu J. Generation of erythroid cells from fibroblasts and cancer cells in vitro and in vivo. Cancer Lett 2013; 333: 205–212.
22 Zhang S, Mercado-Uribe I, Liu J. Tumor stroma and differentiated cancer cells can be originated directly from polyplody giant cancer cells induced by paclitaxel. Int J Cancer 2013; 134: 508–518.
23 Lopez-Sanchez LM, Jimenez C, Valverde A, Hernandez V, Penarando J, Martinez A et al. CoC32, a mimic of hypoxia, induces formation of polyplody giant cells with stem characteristics in colon cancer cells. PLoS One 2014; 9: e99143.
24 Braun EB, Tsai YL, Phoon YP, Landor S, Silva Cascales H, Rasmokd S et al. Loss of CSL unlocks a hypoxic response and enhanced tumor growth potential in breast cancer cells. Stem Cell Rep 2016; 6: 643–651.
25 Niu N, Zhang J, Zhang N, Mercado-Uribe I, Yao F, Han Z et al. Linking genomic reorganization to tumor initiation via the giant cell cycle. Oncogenesis 2016; 5: e261.
26 Zieble N, Edgar BA, DePamphilis ML. Endoreplication. Cold Spring Harb Perspect Biol 2013; 5: a012948.
27 Fox DT, Duronio RJ. Endoreplication and polyplody: insights into development and disease. Development 2013; 140: 3–12.
28 Athayde Wirka K, Chen AA, Conaghan J, Ivanì K, Guakharia M, Behr B et al. Atypical embryo phenotypes identified by time-lapse microscopy: high prevalence and association with embryo development. Fertil Steril 2014; 101: 1637–1648.e1–5.
29 Chavez SL, Loewke KE, Han J, Moussavi F, Colsi P, Munne S et al. Dynamic blastomere behaviour reflects human embryo ploidy by the four-cell stage. Nat Commun 2012; 3: 1251.
30 Hardy K, Winston RM, Handside AH. Binucleate blastomeres in preimplantation human embryos in vitro: failure of cytokinesis during early cleavage. J Reprod Fertil 1993; 98: 549–558.
31 Kligman I, Benadiva C, Allikani M, Munne S. The presence of multinucleated blastomeres in human embryos is correlated with chromosomal abnormalities. Hum Reprod 1996; 11: 1492–1498.
32 Van Royen E, Mangelschots K, Verslyussens M, De Neubourg D, Valkenburg M, Ryckaert G et al. Multinucleation in cleavage stage embryos. Hum Reprod 2003; 18: 1062–1069.
33 Benkhalfa M, Janny L, Vye P, Malet P, Boucher D, Menezos Y. Assessment of polyplody in human morulae and blastocysts using co-culture and fluorescent in situ hybridization. Hum Reprod 1993; 8: 895–902.
34 Vanneste E, Voet T, Le Caing C, Ampe M, Konings P, Melotte C et al. Chromosome instability is common in human cleavage-stage embryos. Nat Med 2009; 15: 577–583.
35 Mertzanidou A, Wilton L, Cheng J, Spits C, Vanneste E, Moreau Y et al. Microarray analysis reveals abnormal chromosomal complements in over 70% of 14 normally developing human embryos. Hum Reprod 2013; 28: 256–264.
36 Ledbetter DH. Chaos in the embryo. Nat Med 2009; 15: 490–491.
